Quarterly report pursuant to Section 13 or 15(d)

License and Collaboration Agreements - Additional Information (Detail)

v3.21.2
License and Collaboration Agreements - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
License Collaboration And Manufacturing Agreements [Line Items]              
License and collaboration revenue     $ 3,870,000 $ 0 $ 7,422,000 $ 0  
Deferred revenue   $ 33,455,000 40,968,000   40,968,000   $ 33,455,000
Deferred revenue   27,795,000 22,470,000   22,470,000   27,795,000
Bayer License Agreement              
License Collaboration And Manufacturing Agreements [Line Items]              
Upfront cash payment received   45,000,000.0          
Additional reimbursement payment for research and process development   15,000,000.0          
Additional upfront cash payment entitle to receive for translational activities, invoiced amount   $ 1,300,000         1,300,000
Royalty eligible to receive term after first commercial sale   12 years          
Determined upfront payment for license in order to evaluate transaction price   $ 45,000,000.0          
Determined research and process development activities in order to evaluate transaction price   15,000,000.0          
Determined additional specified translational activities in order to evaluate transaction price   5,000,000.0          
Determined fee constituted entire consideration included in transaction price         13,100,000    
Deferred revenue     63,400,000   63,400,000    
Development or sales-based milestone payments received         0    
Bayer License Agreement | Current Liabilities              
License Collaboration And Manufacturing Agreements [Line Items]              
Deferred revenue     41,000,000.0   41,000,000.0    
Bayer License Agreement | Long-Term Liabilities              
License Collaboration And Manufacturing Agreements [Line Items]              
Deferred revenue     $ 22,400,000   $ 22,400,000    
Bayer License Agreement | Maximum              
License Collaboration And Manufacturing Agreements [Line Items]              
Additional upfront cash payment entitle to receive for translational activities   5,000,000.0         5,000,000.0
Aggregate milestone payments entitle to receive upon achieving certain development, regulatory and commercial milestones   610,000,000.0         610,000,000.0
Bayer Tech Transfer Agreement              
License Collaboration And Manufacturing Agreements [Line Items]              
License agreement percentage 20.00%            
License agreement amount $ 3,100,000            
License agreement total fee $ 15,300,000            
Technology transfer agreements fee remainder         The remainder of the fee will be billed as follows: (i) 40 percent on January 1, 2022, (ii) 20 percent on January 1, 2023 and (iii) 20 percent upon the technology transfer completion.    
Transaction fee price         $ 15,300,000    
Bayer Manufacturing Agreement              
License Collaboration And Manufacturing Agreements [Line Items]              
License agreement percentage 50.00%            
Written acceptance of binding purchase order percentage     50.00%   50.00%    
Bayer Manufacturing Agreement | Maximum              
License Collaboration And Manufacturing Agreements [Line Items]              
Manufacturing services $ 13,100,000            
Bayer Manufacturing Agreement | Minimum              
License Collaboration And Manufacturing Agreements [Line Items]              
Manufacturing services $ 6,600,000            
Bayer Agreements              
License Collaboration And Manufacturing Agreements [Line Items]              
License and collaboration revenue     $ 3,900,000   $ 7,400,000   0
Deferred revenue   $ 61,300,000 $ 63,400,000   $ 63,400,000   $ 61,300,000